How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    NICE integrated topic prioritisation and strategic principles

    Closed for comments This consultation ended on at   Request commenting lead permission

    11 Opportunities for engagement and support before and during the integrated topic prioritisation

    NICE will routinely identify and contact relevant individuals and organisations at planned points in the topic prioritisation process. This usually occurs at topic identification stage, topic briefing development and after NICE prioritisation board meetings.

    Information gathered during engagement and support may be shared (in line with NICE confidentiality policy and agreements) across the NICE teams on a need-to-know basis to support and enhance topic prioritisation decision making. Information sharing is limited to:

    • technology name

    • indication

    • regulatory information

    • engagement information:

      • date of engagement

      • type of engagement or service used

      • information about the technology or its regulatory information, or both.

    11.1 Tell NICE about a topic

    There will be a common proforma for topic suggestions, with a single letterbox or email: topics@nice.org.uk.

    Additionally, information about topics can be provided directly to:

    • NICE's interventional procedures notification page (for interventional procedures).

    • UK PharmaScan (for medicines).

    • NHS Innovation Service (for devices, diagnostics and digital health technologies).

    • NICE's topic intelligence and monitoring team (for any other topic).

    • NICE Advice can help inform market access strategies for all types of technology. They can provide help to understand the healthcare landscape, identify the most appropriate route to NHS access, and explore the value of the technology with system stakeholders.

    • NICE Advice can also help companies develop evidence that demonstrates the clinical and cost effectiveness of all types of technology. They provide feedback on evidence generation plans, and help companies understand health technology assessment and the perspective of decision makers. NICE Advice also provides a comprehensive peer review service for economic models that helps companies optimise the model's structure, computation, coding, usability and transparency.

    • For medicines that have been selected for NICE guidance, the NICE commercial and managed access teams can arrange discussions between NICE, NHS England (NHSE) and companies. This supports timely discussions to address issues of value, affordability and transactability, as appropriate, to give patients the fastest possible access to clinically and cost-effective treatments. Companies can email NICE's Commercial Liaison Team (which includes NICE's Patient Access Schemes Liaison Unit [PASLU]). The Commercial Liaison Team will then arrange discussions with the Managed Access Team at NICE or the NHSE Commercial Medicines Directorate, or both, as necessary.